MARKET

GLYC

GLYC

Glycomimetics
NASDAQ
3.180
+0.330
+11.58%
Closed 17:24 03/27 EDT
OPEN
2.910
PREV CLOSE
2.850
HIGH
3.180
LOW
2.810
VOLUME
675.05K
TURNOVER
0
52 WEEK HIGH
3.530
52 WEEK LOW
1.110
MARKET CAP
204.77M
P/E (TTM)
-4.9953
1D
5D
1M
3M
1Y
5Y
Positive Outlook for GlycoMimetics: Buy Rating Affirmed Amid Anticipated Pivotal Trial Results and Strategic Growth Initiatives
TipRanks · 15h ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The company's Q4 earnings report came out today. Fresh2 Group stock rose upwards by 5.26% as well.
Benzinga · 20h ago
GlycoMimetics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 22h ago
GlycoMimetics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 22h ago
Buy Recommendation for GlycoMimetics Based on Promising Upro Drug Prospects and Strong Pipeline
TipRanks · 1d ago
Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)
TipRanks · 1d ago
GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023
GlycoMimetics reported earnings per share of -14 cents. This was above the analyst estimate for EPS of -15 cents. The company reported revenue of $10,000. The stock was down 2.7% after the market closed on Wednesday.
Investorplace · 1d ago
Buy Rating on GlycoMimetics Backed by Strong Financials and Promising Phase 3 Trial of Uproleselan
TipRanks · 1d ago
More
About GLYC
GlycoMimetics, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of glycomimetic drugs. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. It is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. The Company is engaged in advancing other preclinical-stage programs, including small-molecule glycomimetic compounds that inhibit the protein galectin-3.

Webull offers GlycoMimetics Inc stock information, including NASDAQ: GLYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLYC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLYC stock methods without spending real money on the virtual paper trading platform.